疫苗诱导免疫性血栓性血小板减少症的临床与实验室诊断
该研究纳入加拿大2021年4月至7月156例疑似疫苗诱导免疫性血栓性血小板减少症(VITT)患者,以血小板因子4(PF4)-14C-血清素释放试验(SRA)为参考,评估多种实验室检测的性能。43例(27.6%)血清学确诊VITT,商业抗PF4/肝素EIA、自建抗PF4-EIA和抗PF4/肝素-EIA对确诊样本敏感性均为100%,平均特异性95.6%;标准SRA和PF4/肝素-SRA特异性100%但敏感性低。作者认为直接检测PF4或PF4/肝素抗体的EIA性能优异,在PF4-SRA不可用时可能作为诊断检测。
要点
- VITT发生于腺病毒载体COVID-19疫苗接种后5至30天,需临床与实验室评估。
- 以PF4-SRA为参考,156例疑似患者中43例(27.6%)血清学确诊VITT。
- 三种EIA对确诊样本敏感性100%,平均特异性95.6%,SRA敏感性低。
核心结论
- 直接检测PF4或PF4/肝素抗体的EIA具有优异性能特征,在PF4-SRA不可用时可能作为诊断检测。
研究设计与样本
- 研究纳入加拿大2021年4月至7月156例疑似VITT患者的临床信息和血样本,以PF4-14C-SRA为参考评估多种实验室检测性能。
主要发现
- 43例(27.6%)基于PF4-SRA阳性血清学确诊VITT,113例(72.4%)为VITT阴性。
- 商业抗PF4/肝素EIA、自建抗PF4-EIA和抗PF4/肝素-EIA对全部43例确诊样本均为阳性(敏感性100%),有少数假阳性,平均特异性95.6%。
- 三种免疫 assay 特异性分别为95.6%(95%CI 90.0-98.6)、96.5%(95%CI 91.2-99.0)和97.4%(95%CI 92.4-99.5)。
- 标准SRA和PF4/肝素-SRA特异性均为100%,但对VITT的敏感性分别为16.7%(95%CI 7.0-31.4)和46.2%(95%CI 26.6-66.6)。
关键数值与推荐
- VITT血清学确诊依据为PF4-SRA阳性。
- 商业抗PF4/肝素EIA(PF4 Enhanced;Immucor)、自建抗PF4-EIA和抗PF4/肝素-EIA对确诊样本敏感性100%,平均特异性95.6%。
- 标准SRA敏感性16.7%(95%CI 7.0-31.4),PF4/肝素-SRA敏感性46.2%(95%CI 26.6-66.6),两者特异性均100%。
临床怎么用
- 作者认为直接检测PF4或PF4/肝素抗体的EIA性能优异,在PF4-SRA不可用时可能作为诊断检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious adverse syndrome occurring 5 to 30 days after adenoviral vector COVID-19 vaccination. Therefore, a practical evaluation of clinical assessments and laboratory testing for VITT is needed to prevent significant adverse outcomes as the global use of adenoviral vector vaccines continues. We received the clinical information and blood samples of 156 patients in Canada with a suspected diagnosis of VITT between April and July 2021. The performance characteristics of various diagnostic laboratory tests were evaluated against the platelet factor 4 (PF4)-14C-serotonin release assay (SRA) including a commercial anti-PF4/heparin immunoglobulin G (IgG)/IgA/IgM enzyme immunoassay (EIA, PF4 Enhanced; Immucor), in-house IgG-specific anti-PF4 and anti-PF4/heparin-EIAs, the standard SRA, and the PF4/heparin-SRA. Of those, 43 (27.6%) had serologically confirmed VITT-positive based on a positive PF4-SRA result and 113 (72.4%) were VITT-negative. The commercial anti-PF4/heparin EIA, the in-house anti-PF4-EIA, and anti-PF4/heparin-EIA were positive for all 43 VITT-confirmed samples (100% sensitivity) with a few false-positive results (mean specificity, 95.6%). These immunoassays had specificities of 95.6% (95% confidence interval [CI], 90.0-98.6), 96.5% (95% CI, 91.2-99.0), and 97.4% (95% CI, 92.4-99.5), respectively. Functional tests, including the standard SRA and PF4/heparin-SRA, had high specificities (100%), but poor sensitivities for VITT (16.7% [95% CI, 7.0-31.4]; and 46.2% [95% CI, 26.6-66.6], respectively). These findings suggest EIA assays that can directly detect antibodies to PF4 or PF4/heparin have excellent performance characteristics and may be useful as a diagnostic test if the F4-SRA is unavailable.
引用
- Bissola AL, Daka M, Arnold DM, et al. The clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia. Blood Adv. 2022. PMID: 35609563. doi:10.1182/bloodadvances.2022007766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。